First-line treatment with ceftriaxone for Neisseria gonorrhoeae infection less likely to be prescribed to patients with a penicillin allergy label: a retrospective audit of medical records
Sexual Health · 2024
DOI: 10.1071/sh24066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sexual Health, 2024. Verfasst von E Durban und 3 weiteren Autor:innen. Beteiligte Einrichtung: Research School of Biology, Australian National University, Canberra, ACT, Australia. Hauptthemen laut MEDLINE: Gonorrhea, Ceftriaxone, Anti-Bacterial Agents, Penicillins. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Capital Territory Health Scholarship.
Abstract (Originalsprache)
Background
Gonorrhoea notifications have increased substantially in Australia over the past decade. Neisseria gonorrhoeae is already highly resistant to several antibiotics and so, alternatives to first-line treatment are generally strongly discouraged. The penicillin allergy label (AL) on patient medical records has previously been shown to influence prescribing practices, to the detriment of best-practice management and antimicrobial stewardship. This study aimed to understand how the penicillin AL influences antibiotic selection for gonorrhoea treatment at Canberra Sexual Health Centre.
Methods
A retrospective chart audit of gonorrhoea cases treated at Canberra Sexual Health Centre between January 2020 and October 2023 (n = 619 patients, n = 728 cases). Antibiotic selection was assessed according to penicillin AL status. Ceftriaxone selection was assessed according to penicillin allergy severity reported in the medical records and as determined using a validated antibiotic allergy assessment tool.
Results
Cases with a penicillin AL were more likely to receive antibiotics other than ceftriaxone (n = 7/41, 17.1%) than cases without the label (n = 8/687, 1.2%, P < 0.000). Most penicillin ALs had non-specific severity ratings in the medical records, but had insufficient information (n = 28/41, 68.3%) to apply the assessment tool. Those reported as low-severity in the records were more likely to receive ceftriaxone (n = 21/22, 95.5%) than those reported as moderate–high (n = 7/11, 63.6%) or unreported (n = 6/8, 0.75%).
Conclusions
Treatment of gonorrhoea in outpatient settings requires an understanding of penicillin allergy, and the ability to quickly and accurately identify penicillin-AL patients who can safely tolerate ceftriaxone. Institutionally endorsed penicillin allergy de-labelling protocols and access to easy-to-navigate prescribing advice within national sexually transmitted infection management guidelines would support this.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research School of Biology, Australian National University, Canberra, ACT, Australia.
- Canberra Sexual Health Centre, Canberra Health Services, Garran, ACT, Australia.
- Canberra Sexual Health Centre, Canberra Health Services, Garran, ACT, Australia; and School of Medicine and Psychology, Australian National University, Canberra, ACT, Australia.
Förderung
- Australian Capital Territory Health Scholarship
Zitieren
APA
Durban, E., English, K., Evans, R., & Martin, S. (2024). First-line treatment with ceftriaxone for Neisseria gonorrhoeae infection less likely to be prescribed to patients with a penicillin allergy label: a retrospective audit of medical records. Sexual Health. https://doi.org/10.1071/sh24066
Vancouver
Durban E, English K, Evans R, Martin S. First-line treatment with ceftriaxone for Neisseria gonorrhoeae infection less likely to be prescribed to patients with a penicillin allergy label: a retrospective audit of medical records. Sexual Health. 2024. doi:10.1071/sh24066
BibTeX
@article{Durban2024,
author = {Durban, E and English, K and Evans, R and Martin, S},
title = {First-line treatment with ceftriaxone for Neisseria gonorrhoeae infection less likely to be prescribed to patients with a penicillin allergy label: a retrospective audit of medical records},
journal = {Sexual Health},
year = {2024},
doi = {10.1071/sh24066}
}
EUVIMED